Biologics Top Stories UK’s MHRA Accepts Biosplice’s Application for Lorecivivint (LOR) in Knee Osteoarthritis and Begins Assessment byNoah SimmonsSeptember 8, 2026
Regulatory Spine Top Stories SpinaFX Medical receives FDA Investigational Device Exemption (IDE) for Triojection®, its Breakthrough, Minimally-Invasive, Image-Guided Lumbar Disc Treatment. byJosh SandbergJune 9, 2026
Biologics Extremities Spine Pacira Biosciences Joins PROBE Consortium to Transform Osteoarthritis Research and Care byJosh SandbergDecember 19, 2025
Neuro Sports Medicine SPRI and Neuromuscular Dynamics Launch NIH-Funded Clinical Trial to Advance Non-Surgical Knee Osteoarthritis Treatment byTim AllenNovember 18, 2025
Biologics Regulatory Doron Therapeutics Announces First Patients Dosed in Phase 3 Study of MOTYS (PTP-001) for the Treatment of Osteoarthritis of the Knee byTim AllenOctober 17, 2025
Spine Top Stories RevBio Receives a $2.2 Million Phase II NIH Grant to Further Develop the Minimally Invasive Use of TETRANITE® to Treat Complex Spine Fractures byTim AllenOctober 6, 2025
Regulatory U.S. FDA approves TREMFYA® (guselkumab) for the treatment of pediatric plaque psoriasis and active psoriatic arthritis, marking a first and only approval for an IL-23 inhibitor byNoah SimmonsSeptember 29, 2025
Regulatory Top Stories CurvaFix Secures FDA Clearance to Advance Pelvic Fracture Treatment byTim AllenSeptember 3, 2025
Financial Spine Degenerative Disc Disease Treatment Market is Expected to Reach Revenue of USD 66.2 Bn by 2033, at 7.7% CAGR: Dimension Market Research byTim AllenOctober 8, 2024
Spine Aclarion Launches the Clinical Utility and Economic (CLUE) Trial to Quantify How Often Nociscan’s AI Generated Biomarker Data Changes Surgical Treatment Plans byJosh SandbergAugust 21, 2024
